Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Aerobiology and pollution (41)
  • Allergen immunotherapy (81)
  • x AllergoOncology (15)
  • Allergy asthma and a sport (4)
  • Allergy diagnosis (235)
  • x Allied health and primary care (20)
  • Anaphylaxis (113)
  • Artificial Intelligence (12)
  • Asthma (185)
  • Basic immunology (58)
  • Biologicals (90)
  • Biomarkers (64)
  • Comparative veterinary allergology (1)
  • COVID19 (11)
  • Dermatology (125)
  • Drug allergy (172)
  • ENT (29)
  • Environmental allergy and climate change (31)
  • Eosinophilic esophagitis (21)
  • Epidemiology (66)
  • Epithelial cell biology (8)
  • Food allergy (195)
  • Genomics and proteomics (17)
  • Immune deficiencies and autoimmunity (80)
  • Immunomodulation and nutrition (13)
  • Infections (27)
  • Insect venom hypersensitivities (19)
  • Mastocytosis and mast cells (24)
  • Microbiome (9)
  • Occupational allergy (27)
  • Ocular allergy (5)
  • One Health (13)
  • Pediatrics (144)
  • Prevention (40)
  • Systems medicine (13)
Poster available until
  • Until platform closure (1)
Poster categories
  • e-Thematic Poster Session (4)
  • Thematic Poster Session (29)
keywords
Session Reference
  • L-TPS07 (1)
  • L-TPS08 (7)
  • L-TPS12 (1)
  • L-TPS14 (1)
  • L-TPS21 (4)
  • TPS03 (1)
  • TPS11 (1)
  • TPS25 (1)
  • TPS28 (1)
  • TPS48 (1)
  • TPS51 (1)
  • TPS52 (1)
  • TPS54 (1)
  • TPS63 (1)
  • TPS69 (8)
35 results
Thumbnail

D3.390 - Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Thumbnail

D3.391 - Results from the ALPHA-STAR Trial, a Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Navenibart in Participants with Hereditary Angioedema (HAE)

Thumbnail

D3.392 - What information and education is crucial for people with food allergies?

Thumbnail

D3.393 - Daily life with a peanut allergy, as a young adult- an interview study

Thumbnail

D3.394 - Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks in Patients from Italy

Thumbnail

D3.395 - Evaluation for suspected penicillin allergy - the patient perspective

Thumbnail

D3.398 - Food provision experience of inpatients with adverse food reactions in the acute hospital setting

Thumbnail

D1.388 - Frequency of Allergic Diseases in Various Age Groups

Thumbnail

D1.389 - How Youth Understand and Manage Risks Associated with Their Food Allergy in Everyday Life

Thumbnail

D1.390 - Long-term safety and efficacy of navenibart in participants with hereditary angioedema (HAE): Initial combined results from ALPHA-STAR and ALPHA-SOLAR

Thumbnail

D1.391 - Comparing Dietary Advancement Therapy for IgE-Mediated Egg Allergy in Primary and Tertiary Care: A Retrospective Review

Thumbnail

D1.392 - Allergic Rhinitis Patients Appear to be at Risk of Lower Quality of Life and Higher Probability of Moderate or Severe Anxiety: Results of an Online Survey in Lithuania

Thumbnail

D1.393 - Building Local Capacity and Improving Access to Specialist Allergist Care for Indigenous Patients in Northern Quebec, Canada

Thumbnail

D1.394 - Characteristics, healthcare provision and expectations of patients with atopic dermatitis as part of the ADCompanion study to evaluate a digital form of care

Thumbnail

D1.43 - Performance Evaluation of a Semi-Quantitative Rapid Test Kit for Dust Mites: For Home Self-Monitoring and Control Effectiveness Assessment

Pagination

  • First page First
  • Previous page Previous
  • Page 1
  • Current page 2
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM